Share
تجربة المرضى مع العلاجات البيولوجية الوريدية للمرضى العراقيين المصابين بامراض المفاصل == Patients Experience with Intravenous Biologic Therapies in Iraqi Patients with Rheumatologic Diseases
Author name:
ندى علي محمد
Supervisor name:
زياد شفيق الراوي
General topic:
Medicine
Specific topic:
Diseases - Joints
Degree:
Higher Diploma
University:
University of Baghdad - Faculty Of Medicine - Department Of Medicine
Language:
English
University location:
Baghdad
First pages:
19T1391 - p.pdf
Abstract:
Intravenous and subcutaneous administration of biologic agents differs not only in routes of administration but also in dosing schedules, costs, onset of efficacy, and immunogenicity which are associated with patients‟ preferences and corresponding persistence in treatment utilization. Additionally, injection issues (depending on route of administration and agent type) have been shown to influence patients‟ utilization of biologic therapies.ObjectiveThe main objective of this study was to describe patients experience with intravenous (IV) biologics for specific rheumatologic conditions including rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Patients and Methods A cross - sectional study was conducted through interviews of 196 patients with the above mentioned autoimmune diseases who were currently receiving an IV biologics at Baghdad Teaching Hospital. Patients were asked to describe the advantages and disadvantages associated with their IV infusion experience. ResultsOn a 7 - point Likert scale (1= not at all satisfied; 7= very satisfied), 90.3% of patients rated satisfaction as 5, 6 or 7. The most frequently perceived benefit of IV therapy were related to Infusion center visits which act as an additional assessment to a regular doctor visit which was equals to 88.8% of patients. Fifty one percent of patientsexperienced t “No disadvantage” in receiving IV biologic therapy and 25% of patients reported that the duration of infusion takes too long as perceived disadvantages. The two most common reasons for preferring IV therapy were the less frequent dosing regimenreported by 81.6 % of patients and 54.1% of patients believes that the intravenous infusion was always effective and they have no experience with subcutaneous therapy.ConclusionsPatients using IV biologics are highly satisfied with their medications and their preferences are due to less frequent dosing, the perceived IV injection effectiveness and the easier to remember dosing when an appointment is scheduled for them.
